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Use of Neem oil and
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treatment of calcinosis-
related skin ulcers in
systemic sclerosis
Dilia Giuggioli1, Federica Lumetti1,
Amelia Spinella1, Emanuele Cocchiara1 ,
Gianluca Sighinolfi2, Giorgia Citriniti1,
Michele Colaci3, Salvarani Carlo4 and
Clodoveo Ferri1
Abstract
Objective: This study evaluated Neem oil and Hypericum perforatum (HoloilV
R
) for treatment of
scleroderma skin ulcers related to calcinosis (SU-calc).
Procedure: We retrospectively analyzed 21 consecutive systemic sclerosis (SSc) patients with a
total of 33 SU-calcs treated daily with HoloilV
R
cream compared with a control group of 20
patients with 26 SU-calcs. HoloilV
R
was directly applied to skin lesions, while the control group
received only standard medication.
Results: Application of HoloilV
R
either resulted in crushing and complete resolution of calcium
deposits or facilitated sharp excision of calcinosis during wound care sessions in 27/33 cases
(81.8%). Complete healing of SU-calc occurred in 15/33 (45%) of cases within a time period of
40.1 16.3 (mean SD) days, while 18/33 (55%) of lesions improved in terms of size, erythema,
fibrin and calcium deposits. Patients reported a reduction of pain (mean numeric rating scale 7.3
 1.9 at baseline versus 2.9 1.4 at follow-up) The control group had longer healing times and a
higher percentage of infections.
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Conclusions: The efficacy of local treatment with neem oil and Hypericum perforatum suggest
that HoloilV
R
could be a promising tool in the management of SSc SU-calc.
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Introduction
Skin ulcers are one of the most frequent
manifestations of systemic sclerosis (SSc).
Skin ulcers frequently cause pain and dis-
ability, and may severely affect the quality
of life of SSc patients. Standard systemic
and local treatments may promote healing
of digital ulcers and reduce the incidence
of new-onset lesions.1 Skin ulcers associat-
ed with SSc encompass all cutaneous
ulcerative lesions, while digital ulcers
refers to lesions localized to fingertips,
toe tips and/or close to the nails.
However, a significant percentage of SS-
associated skin ulcers are challenging to
treat, mainly due to complicating infec-
tions or localization of lesions to cutane-
ous calcinosis (SU-calc).2
Calcinosis consists of deposits of calcium
salts in the skin and subcutaneous tissues3,4
and affects up to 25% of SSc patients.
Calcinosis generally develops several years
following initial SSc diagnosis.5–7 Calcium
deposits may have different sizes, shapes
and localization; areas subjected to recur-
rent trauma, such as fingers and extensor
articular surfaces are the most frequently
involved. The typical symptoms are pain
(usually described as stabbing) and func-
tional limitation of involved joints.
Calcinosis per se is very difficult to treat
and is frequently complicated with skin
ulceration, fistulisation and supra-infec-
tion,8–9 requiring antibiotic administration
and/or surgical removal. Currently, no local
or systemic treatments are available for
SU-calc.10
Standard local therapies include debride-
ment, disinfection and dressing ulcers with
hydrogel or antiseptic dressings. These pro-
cedures are performed according to wound
bed preparation principles as summarized
in the acronym TIME: necrotic Tissue,
Infection/inflammation, Moisture balance
and Epithelization. Addressing the most
important aspects of ulcer evaluation and
management helps to accelerate healing of
spontaneous ulcers.11
Hypericum perforatum and Azadirachta
indica are plants with therapeutic properties.
Their extracts have a wide range of medical
applications, including the management of
skin wounds, eczema, and burns.12–17 The
aim of this study was to evaluate the efficacy
of HoloilVR , a mixture of Neem oil (an extract
from the fruits and seeds of Azadirachta
indica) and Hypericum perforatum, for treat-
ing SU-calc in SSc patients in addition to
standard local treatment.
Patients and methods
We consecutively enrolled SSc patients with
SU-calc referred to our scleroderma unit
over the past year. We evaluated the effects
of HoloilVR for local treatment of SU-calcs
in these patients. Over the same period, a
group of SSc patients with comparable
SU-calcs was also consecutively evaluated
as controls. All patients satisfied the ACR/
EULAR 2013 classification criteria.18
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Patient clinical data were carefully eval-
uated on the basis of individual medical
records including demographic and
clinico-serological findings, SU-calc fea-
tures (shape, consistency, localization, pres-
ence of exudates, smell and/or other signs
of infection), and radiological imaging of
the calcinotic area. Calcium deposits were
also classified according to their shape and
consistency on palpation into mousse (soft,
chalky-like liquid underneath the skin)
(Figure 1a), plate (palpable as large uni-
form agglomerate) (Figure 1b) and stone
(palpable as a single stone or agglomerates
of multiple stones of hard consistency)
(Figure 1c). All patients were treated with
standard systemic therapy for scleroderma
vasculopathy at the time of SU-calc presen-
tation using one or more vasoactive drugs.
Local treatment of single SU-calcs was car-
ried out according to the wound bed prep-
aration model, mainly based on the extent
and depth of debridement of skin
lesions.2,11,19
Debridement sessions were performed in
our SSc skin ulcer clinic, and followed a
treatment schedule tailored to individual
patients on the basis of general clinical con-
dition, severity of each cutaneous lesion,
and potential complications such as local
infections.9 After adequate preparation of
the wound bed, HoloilVR cream was applied
directly to the lesion and covered with non-
adhesive gauze. The first HoloilVR adminis-
tration was performed in our clinic, then
patients were instructed to apply the
cream daily at home. All patients were sys-
tematically re-evaluated and locally treated
every 2 weeks by trained rheumatologists.
Patients in the control group were also
treated using standard systemic and local
therapy without HoloilVR .
Each patient was also instructed to
record the following data daily: pain level
on a 0–10 severity scale (NRS: numeric
rating scale), use of analgesics, adverse reac-
tions to wound dressing, clinical features of
perilesional skin (maceration, excoriation),
Figure 1a. Based on shape and consistency on
palpation, calcinosis was classified as mousse (soft,
chalky-like liquid underneath the skin).
Figure 1b. Based on shape and consistency on
palpation, calcinosis was classified as plate (palpable
as large uniform agglomerate).
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clinical signs of local infection (erythema,
smell, swelling, increasing pain), and com-
pliance in administering local medication
(scored as 0: no difficulty, 1–2: mild-
moderate difficulty, and 3: incapable of
administering medication).
The study was approved by the local
Ethical Committee (protocol n. 282/15),
and written informed consent was obtained
from all participants.
Statistical analysis
Using Fisher’s exact test, we estimated odds
ratios (ORs and 95% confidence intervals)
to compare the responses of scleroderma
SU-calcs in patients treated with HoloilVR
and control patients. Quantitative variables
were reported as of means and standard
deviation (SDs). Differences between
groups were assessed using unpaired
t-tests in GraphPad Prism 5 software.
Results
We consecutively enrolled 21 SSc patients
with SU-calc and evaluated the effects of
HoloilVR for local treatment of 33 SU-calcs
in these patients (21 F patients, meanSD
age 61.1 15.0 years, mean SD disease
duration 15.2 9.4 years). Over the same
period, 20 SSc patients with 26 comparable
SU-calcs was also consecutively evaluated
as controls (20 F controls, meanSD age
57.3 13.2 years, meanSD disease dura-
tion 14.3 8.6 years). In total, 19/2 patients
in the HoloilVR group showed limited/diffuse
cutaneous SSc, while 17/3 patients in the
control group showed limited/diffuse cuta-
neous SSc (Table 1). Sixteen patients were
receiving long-term treatment with calcium-
channel-blockers, 21 were receiving intrave-
nous prostanoids, and 12 were receiving
anti-endothelin-1 therapy.
The characteristics of SU-calcs and their
responses to HoloilVR , as well as the results
observed in the control group, are shown in
Table 1. The majority of the SU-calcs were
localized to the fingertips (26, 78.8%),
elbows (3, 9.1%), knees (2, 6.1%) and
more rarely on the wrists and forearms
(3%). Calcium deposits were palpable at
physical examination as stone/plate in 32/
33 (97.0%) or as mousse in 1/33 (3.0%) of
all cases confirmed by X-ray examination.
Comparable SU-calc clinical features were
observed in the control group.
The presence of SU-calc was associated
with pronounced signs of local inflammato-
ry reactions such as edema involving
the surrounding skin (80%). At baseline
6/33 (18.2%) SU-calc showed clear
signs of infection; the bacteria involved
were Staphylococcus aureus (3 cases),
Stenotrophomonas maltophilia (1),
Staphylococcus hominis (1), and Escherichia
coli (1). Systemic antibiotic therapy was
required for 4/6 SU-calcs, whilst HoloilVR ’s
application was able to control infection in
2/6 infected lesions. Additional or relapsing
infections were not observed during the
follow-up period.
In all patients, application of HoloilVR
after sharp debridement either caused pro-
gressive crushing and resolution of calcium
Figure 1c. Based on shape and consistency on
palpation, calcinosis was classified as stone (palpa-
ble as a single stone or agglomerates of multiple
stones of hard consistency).
4 Journal of International Medical Research 0(0)
deposits or eased their sharp excision
during wound care session (27/33 cases,
81.8%). Apart from the single lesion pre-
senting as mousse calcinosis, stone calcino-
sis evolved to mousse deposits during
HoloilVR applications in another five cases,
allowing their removal by applying simple
pressure on the SU-calc area (total 6/33;
18%) (Figure 1a). Surgical removal was
necessary in only 1/33 cases (3.0%).
Overall, the diameters of SU-calcs during
treatment decreased in 27/33 cases
(81.8%) with formation of granulation
tissue and regularization of margins, with
complete healing recorded in 15/33 cases
(45.4%) after a time interval of 40.1 16.3
(mean SD) days. A significant improve-
ment (reduction of lesion size, erythema,
fibrin and calcium deposits) was observed
for the remaining lesions, and no lesions
relapsed during the entire follow-up period.
Figure 2 shows the activity of HoloilVR on
lesions over time. After an initial debride-
ment, application of Holoil allowed the for-
mation of mousse deposits and eased
removal of the calcifications.










Patients 21 20 /
Calcinosis SU 33 26 /
Localization
Fingertips 26 (78.8) 19 (73.1) /
Elbows 3 (9.1) 2 (7.7) /
Knees 2 (6.1) 3 (11.6) /
Forearms 1 (3.0) 1 (3.8) /
Wrists 1 (3.0) 1 (3.8) /
Shape and consistency at baseline
Stone/Plate 32 (97.0) 24 (92.3) /
Mousse 1 (3.0) 2 (7.7) /
Infections
S. aureus, S. maltophilia, S. hominis, E. coli 6 (18.2) 14 (53.8) 0.0058*
Antibiotic request 4 (12.1) 11 (42.3) 0.0146*
Treatment
Debridement 33 (100) 26 (100)
þ HoloilVR alone 26 (78.8) – <0.0001*
þ Pressure on SU-cal as mousse 6 (18.2) – 0.0297*
þ Surgical removal 1 (3.0) 6 (23.1) 0.0367*
Skin ulcer change
Healing 15 (45.4) 4 (15.4) 0.0237*
Improvement 18 (54.6) 22 (84.6) ns
Time Healing (days) 40.1 16.3 96.3 10.7 0.0001*
NRS (0–10; mean SD)
Baseline 7.3 1.9 7.5 2.1 0.7506
End of follow-up 2.9 1.4 4.5 2.4 0.0124*
HoloilV
R
adherence 33 (100) – /
HoloilV
R
side effects (persistent erythema) 1 (3.0) – /
*p value< 0.05.
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Patients in the control group reported
less satisfactory outcomes, with longer heal-
ing times (96.3 10.7 days, mean SD;
p< 0.0001) and frequent infectious compli-
cations requiring systemic antibiotic treat-
ment (42.3% vs. 12.1% of treated
subjects, p¼ 0.0146). These results sug-
gested that patients treated with Holoil
had a higher degree of protection against
infections than control patients (Table 1).
Prior to receiving SU-calc medication,
local application of EMLA (prilocaine/lido-
caine mixture) permitted good patient com-
pliance during the entire session of
debridement and dressing.20 Only one
patient with particularly severe SU-calc
complicated by infection received intrave-
nous morphine to remove calcinosis.
All patients experienced a significant
reduction in SU-calc-related pain (change
in NRS in treated patients from baseline
to the end of follow-up: 7.3 1.9 to 2.9
1.4 vs. control subjects: 7.5 2.1 to 4.5
2.4; p¼ 0.0124).
The analgesic demand for pain control
gradually reduced over time. Opioids were
required in all patients at baseline, whilst
paracetamol was sufficient for pain control
at the end of follow-up only in patients
treated with HoloilVR .
Complete adherence to treatment with
HoloilVR was observed for all SSc patients.
Moreover, self-medications were also con-
sidered “easy to use” (score 0) in all cases.
Treatment with HoloilVR was generally
well tolerated, with only 2/21 patients
reporting a mild burning sensation during
the first HoloilVR treatment that subsequent-
ly disappeared. In only one case, persistent
erythema with burning and excoriation of
the perilesional skin occurred, requiring
HoloilVR suspension.
Discussion
Cutaneous calcinosis may severely affect
the quality of life of SSc patients because
of the frequent complications of non-
healing SU-calcs. Although frequently
detectable during the course of the disease,
very few data are available to inform the
correct clinical assessment and management
of these specific manifestations.3
Over the last two decades we evaluated
the usefulness of numerous systemic and
local treatment combinations adapted to
different clinico-pathogenetic variants of
scleroderma skin ulcers. These are regularly
tailored to individual patients. The present
study describes our experience with local
HoloilVR treatment in addition to standard
of care for SU-calc. Application of HoloilVR
after lesion debridement3 resulted in pro-
gressive crushing of calcium deposits and
allowed sharp excision of calcinosis for the
large majority of SU-calcs. Interestingly, in
five cases the stone calcinosis evolved to
mousse deposits, making their removal
Figure 2. Hand calcinosis (SU-calc) evolution following HoloilV
R
use. In the sequence (a–d) the easy removal
of calcium deposits can be observed, thanks to liquefaction induced by the medication (Figure 2) [AQ1].
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easier by applying pressure on the wound
area. At the end of follow-up, complete
healing of the SU-calc was observed in
about half of cases. Moreover, a progres-
sive reduction of pain and analgesic
demand, as well as good compliance and
tolerance to the combined treatment regi-
men, were recorded for all patients.
Compared with the HoloilVR treated group,
control patients treated with standard ther-
apies showed less satisfactory outcomes,
with significantly longer healing times
(p< 0.0001) and a higher percentage of
infectious complications.
According to previous clinical observa-
tions, SU-calcs are more frequently local-
ized on fingertips, elbows, and/or knees,
and are potentially associated with hypoxia
and recurrent trauma.2,3 Pharmacological
treatment to reduce calcinosis and diminish
the risk of harmful SU-calcs is particularly
challenging, and no efficacious therapies
have been identified to date.22–24 Both
mechanical25 and surgical local approaches
are generally needed in cases resistant to
conventional treatments, and a significant
proportion of patients with large, localized,
and symptomatic lesions require surgical
excision. Saddic et al.26 reported an excel-
lent clinical outcome, including decreased
pain and short healing time, in one patient
with scleroderma SU-calc who underwent
curettage of a calcinosis on the tip of his
left middle finger. However, a potential
risk of surgical excision is delayed wound
healing, which may lead to skin necrosis,
infection, and decreased range of joint
motion.
Our data confirmed the efficacy of local
treatment of SU-calcs in different cutane-
ous disease settings when combined with
Hypericum and Neem oil cream and a
wound bed preparation framework.11,19
Hypericum perforatum is a plant typically
known for its antidepressant properties12
which can be used in treatment of mild
inflammatory dermatological diseases and
even to treat skin wounds in association
with traditional approaches.27 Hyperforin
is the most important active substance pro-
moting wound healing, probably thanks to
its action on fibroblasts, keratinocyte pro-
liferation and differentiation. In addition,
hyperforin has antimicrobial activity, par-
ticularly against Gram-positive bacte-
ria.28,29 Azadirachta indica, commonly
known as Neem, has been proposed as a
potential treatment for many infectious
and metabolic disease.30 Neem oil could
have anti-inflammatory properties by mod-
ulating macrophage migration and activi-
ty31. Thanks to the presence of limonoids,
Neem could represent a safe tool for local
treatment of acute skin toxicity in patients
undergoing radiotherapy or chemo-
radiotherapy for head and neck
malignancies.32
In addition, HoloilVR shows cicatrizing
and bacteriostatic effects that contribute
to wound repair.12,13
The two active components of HoloilVR
potentiate one another to achieve infection
control, inhibition of inflammation, and
induction of epithelization. Only a few
reports have focused on the efficacy of
HoloilVR in wound healing, especially diabet-
ic ulcers and surgical wounds, even those
complicated by bone exposition.16,17 To
our knowledge, no studies have examined
the efficacy of HoloilVR in treating SSc-
related ulcers.
In our experience, HoloilVR cream was
particularly useful for treatment of SU-
calcs, which are difficult to heal because of
constant local inflammation sustained by
calcium deposits and frequently complicat-
ed by infections. In the control group,
Staphylococcus aureus, Stenotrophomonas
maltophilia, Staphylococcus hominis, and
Escherichia coli were detected in a signifi-
cant proportion of lesions requiring antibi-
otic therapy. Besides their potential role in
control of infections,29 Neem and
Hypericum mixtures may also contribute
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to calcium deposit crushing, thus facilitat-
ing the removal of stones during curettage.
Wound bed conditions, once deprived of
the inflammatory stimulus exerted by calci-
nosis, rapidly improved with growing of
granulation tissue, reduced fibrin, and re-
epithelization of the edges. Overall, a bene-
ficial effect of HoloilVR was invariably
observed to some degree in our patients,
contrary to the control group. These pre-
liminary positive effects, along with the
patients’ good compliance and the low
costs of treatment, suggest that HoloilVR
could represent an additional, promising
tool in the management of difficult-to-heal
SU-calcs in scleroderma patients.
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